NEW YORK (360Dx) – Grifols said today that it has inked an exclusive, long-term agreement with Beckman Coulter for the global distribution of Grifols' hemostasis instruments, reagents, and consumables.
The firms expect that under the distribution agreement, the first commercial systems will be available in Europe in early 2018.
Additional terms were not disclosed.
Arnd Kaldowski, president of Beckman Coulter Diagnostics, said in a statement that the long-term agreement "expands our extensive diagnostic product offering and further supports our position as a partner of choice with hospitals and clinical laboratories across the world."
Carsten Schroeder, Grifols president of diagnostic commercial operations, said that its hemostasis product line "complements Beckman Coulter's broad portfolio of products and services for the core laboratory," as Grifols continues to execute its strategy in growing a specialty diagnostics line.